Showing results (11-20 of 255) with videos related to
Sort By:
Pageof 26
Clinical and Experimental Rheumatology|November 24, 2004
Tuberculosis and opportunistic infections: relevance to biologic agentsJ Bieber, A KavanaughClinical and Experimental Rheumatology|November 9, 2005
The assessment of disease activity and outcomes in psoriatic arthritisA Kavanaugh, S CassellRheumatology (Oxford, England)|January 26, 2000
The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapiesP E Lipsky, A KavanaughClinical and Experimental Rheumatology|February 19, 2004
The safety of biologic agents in early rheumatoid arthritisA Kavanaugh, E C KeystoneThe Journal of Extra-Corporeal Technology|February 6, 1998
Perfusion services national process improvement benchmarkingJ B Riley, T A KavanaughPlos Genetics|January 3, 2009
Non-coding RNA prediction and verification in Saccharomyces cerevisiaeLaura A Kavanaugh, Fred S DietrichClinical and Experimental Rheumatology|November 24, 2004
Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for "near remission" of DAS or single measuresT Pincus, T Sokka, A KavanaughThe Journal of Rheumatology|April 1, 1995
Central nervous system angiopathy associated with cocaine abuseK Martin, T Rogers, A KavanaughClinical and Experimental Rheumatology|November 24, 2004
Benefit/risk of therapies for rheumatoid arthritis: underestimation of the "side effects" or risks of RA leads to underestimation of the benefit/risk of therapiesT Pincus, A Kavanaugh, T SokkaClinical and Experimental Rheumatology|November 24, 2004
Quantitative documentation of benefit/risk of new therapies for rheumatoid arthritis: patient questionnaires as an optimal measure in standard careT Pincus, T Sokka, A KavanaughPageof 26